Micypra (Cyproterone Acetate, Ethinylestradiol)

Cyproterone acetate acts as a progestogen that suppresses gonadotropin release, preventing ovulation, and it blocks androgen receptors, reducing the effects of excess androgens on the skin and hair follicles.

The dosing regimen for Micypra is determined by the prescribing clinician. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule should follow the prescriber’s instructions.

Micypra is contraindicated in pregnancy (Category X) because it may cause fetal harm. It is also not recommended for breastfeeding women, as hormonal exposure could affect milk production and infant development.

To order Micypra, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Micypra contains cyproterone acetate, which adds anti‑androgenic activity not present in many other combined oral contraceptives. This makes it particularly useful for patients with acne or hirsutism, while still offering the standard contraceptive efficacy of estrogen‑progestogen tablets.

Micypra tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Micypra is taken orally as a tablet, usually once daily at the same time each day. Swallow the tablet whole with water; do not split, crush, or chew unless directed by a healthcare professional.

The most serious risks include venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism, and severe hypertension. Patients should seek immediate medical attention if they experience leg pain, swelling, sudden shortness of breath, or a rapid increase in blood pressure.

Micypra should not be used by women who are pregnant or breastfeeding, smokers over 35 years of age, individuals with a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or hormone‑sensitive cancers such as breast or endometrial carcinoma.